HFS clients enjoy state-of-the-art warehousing, real-time access to critical business data, accounts receivable management and collection, and unparalleled customer service. HFS provides print and digital distribution for a distinguished list of university presses and nonprofit institutions. MUSE delivers outstanding results to the scholarly community by maximizing revenues for publishers, providing value to libraries, and enabling access for scholars worldwide.
Project MUSE is a leading provider of digital humanities and social sciences content, providing access to journal and book content from nearly 300 publishers. With warehouses on three continents, worldwide sales representation, and a robust digital publishing program, the Books Division connects Hopkins authors to scholars, experts, and educational and research institutions around the world.
See the complete profile on LinkedIn and. Susan has 17 jobs listed on their profile. Republican Walker’s 8-point advantage with men has closed to 6, and Warnock’s lead with women has grown from 5 points to 9.
#Susan de francisco iphi professional#
With critically acclaimed titles in history, science, higher education, consumer health, humanities, classics, and public health, the Books Division publishes 150 new books each year and maintains a backlist in excess of 3,000 titles. View Susan Chritton, PCC, CAPP, CCC’S profile on LinkedIn, the world’s largest professional community. 'The gender gap in the Senate race has shifted in the Democrats’ favor since August. The division also manages membership services for more than 50 scholarly and professional associations and societies. Gender Pay Equity Report 21 Elect Susan Mgmt For For For Desmond-Hellmann. The Journals Division publishes 85 journals in the arts and humanities, technology and medicine, higher education, history, political science, and library science. Deere & Company Ticker Security ID: Meeting Date Meeting Status DE CUSIP. The Press is home to the largest journal publication program of any U.S.-based university press. We’re exploring ways to extend these findings to new classes of enzymes and beyond to enable a new/next generation of targeted therapies.One of the largest publishers in the United States, the Johns Hopkins University Press combines traditional books and journals publishing units with cutting-edge service divisions that sustain diversity and independence among nonprofit, scholarly publishers, societies, and associations. We’ve shown that redirecting E3-ubiquitin ligases can efficiently drive degradation of target proteins. Second, we are interested in retargeting native biological activities at both the molecular and cellular level. We’re developing molecules to safely engage important biologies beyond T-cells to drive anti-tumor responses. Despite multiple cell types playing integral roles in adaptive responses, most current approved immuno-oncology therapies are T-cell focused. First, we are exploring ways to modify the tumor microenvironment to enhance anti-tumor immune responses. There are two current areas of particular interest. We advance a variety of therapeutic modalities, including bi- and multispecific antibodies, fusion proteins, antibody drug conjugates, and bioconjugates to enable therapeutic targeting and selective modulation of pathway biology. My lab focuses on developing “smart biologics”- molecules that selectively turn pathways on or off in the location (complex, cell or tissue) of our choosing. Together this allows us to answer important questions about approaches
I find that collaborating with the next generation of scientists helps to ground me in fundamental elements of biochemistry while exploring emerging approaches in biotherapeutic discovery. The unique environment here offers postdocs the opportunity to contribute to basic science while being immersed in both foundational and translational research. I’m always excited to mentor post docs at Genentech. In the department of Antibody Engineering my group focuses on the development of complex biologics and bioconjugates to enable targeted biology that isn’t addressable in other ways. I was instantly attracted to the rigorous scientific focus, collaborative atmosphere, and the abundant creativity of my prospective (now current) colleagues, along with the ability to translate scientific findings to actual human medicines. I joined Genentech as a Scientist in 2016 following academic training in biological chemistry and protein engineering and five years in industry focused on the directed evolution of therapeutic enzymes.
0 kommentar(er)
